Avalo Therapeutics (NASDAQ:AVTX) Given New $10.00 Price Target at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX) had its price objective dropped by investment analysts at BTIG Research to $10.00 in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. BTIG Research‘s price target would suggest a potential upside of 48.26% from the company’s previous close.

A number of other research firms have also issued reports on AVTX. Wall Street Zen lowered shares of Avalo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a report on Friday. Weiss Ratings upgraded shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Leerink Partners initiated coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They issued an “outperform” rating and a $38.00 target price on the stock. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $39.10.

Avalo Therapeutics Stock Down 9.5%

Avalo Therapeutics stock traded down $0.71 during trading on Friday, reaching $6.75. The stock had a trading volume of 2,896,609 shares, compared to its average volume of 1,279,087. The business has a 50 day moving average price of $16.30 and a 200 day moving average price of $16.67. Avalo Therapeutics has a 52-week low of $6.53 and a 52-week high of $24.27. The stock has a market cap of $361.73 million, a PE ratio of -1.54 and a beta of 0.68.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, equities analysts predict that Avalo Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Activity

In other news, CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the sale, the chief financial officer owned 39,900 shares in the company, valued at $651,567. This trade represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,258 shares of company stock worth $415,434 in the last 90 days. Company insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently made changes to their positions in AVTX. Squarepoint Ops LLC grew its position in shares of Avalo Therapeutics by 624.9% during the second quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after buying an additional 507,960 shares in the last quarter. Seven Fleet Capital Management LP grew its position in shares of Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock worth $14,244,000 after buying an additional 196,882 shares in the last quarter. Braidwell LP acquired a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $30,107,000. Wellington Management Group LLP acquired a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $1,945,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $1,897,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics News Roundup

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Wedbush maintained an Outperform rating and set a $22 price target. Although the target was reduced from $34, it still implies substantial potential upside from current trading levels, signaling that the firm views the recent selloff as overdone. Wedbush Adjusts Avalo Therapeutics Price Target
• Positive Sentiment: BTIG Research reduced its price target to $10 but retained a Buy rating, indicating that the analyst still sees value despite lowering its valuation assumptions.
• Neutral Sentiment: Guggenheim reaffirmed its Neutral rating, while HC Wainwright shifted from Buy to Neutral. The changes reflect a more cautious analyst outlook, but neither firm issued a Sell rating.
• Neutral Sentiment: Trading in AVTX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating unusually rapid volatility and triggering an exchange-mandated pause.
• Negative Sentiment: AbbVie’s favorable Phase III HS results weighed on Avalo shares by raising concerns that a competing therapy could reduce Avalo’s future market opportunity or weaken the commercial outlook for its pipeline. AbbVie Phase III Data Subdue Avalo Shares
• Negative Sentiment: The broad reductions in analyst price targets—including Wedbush’s cut from $34 to $22 and BTIG’s move to $10—suggest that expectations for Avalo’s near-term valuation have been reset lower, even though some analysts remain bullish.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.